Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects

PHASE3CompletedINTERVENTIONAL

Enrollment

268

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Ocular Inflammation

Interventions

DRUG

ISV-303

0.075% bromfenac in DuraSite dosed BID

OTHER

DuraSite Vehicle

DuraSite vehicle dosed BID

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT01808547 - Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects | Biotech Hunter | Biotech Hunter